Evgen Pharma PLC Authored Article Publication
19 10월 2023 - 10:26PM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
19 October 2023
Evgen Pharma plc
("Evgen" or the "Company")
Authored Article on Enteric Coating Formula
Alderley Park, UK - 19 October 2023 : Evgen Pharma plc (AIM:
EVG), a clinical stage drug development company developing
sulforaphane-based medicines for the treatment of cancer and other
indications , highlights an article published today in respected
industry publication The Medicine Maker , authored by Evgen's Chief
Business Officer, Dr Helen Kuhlman.
The article, entitled The Sulforaphane Promise, focuses on the
recent study of Evgen's new enteric-coated tablet formulation, and
why enteric coatings are of particular importance for a stabilised
complex such as SFX-01 that releases highly biologically active
sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid
conditions and the enteric coat prevents acid attack in the
stomach, releasing the drug in the ideal region - the small bowel.
It also discusses the pharmacodynamic and pharmacokinetic data from
the recent study, demonstrating the improvements of the tablet
formulation over previous formulations of SFX-01.
The Medicine Maker is an online and print publication based in
the United States, focusing on the entire spectrum of drug
development and with a readership of pharmaceutical industry
professionals across all levels. The article can be read online
here .
-Ends-
Enquiries:
Evgen Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO +44 1625 466591
FinnCap (Nominated Advisor and
Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris evgen@instinctif.com
/ Adam Loudon / Jack Kincade
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. Recently, Evgen completed an out-licensing transaction
with Stalicla SA, a Swiss specialist company in neurodevelopmental
disorders, commencing with autism spectrum disorder. The deal, if
successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAXKLFFXBLLFBZ
(END) Dow Jones Newswires
October 19, 2023 09:26 ET (13:26 GMT)
Evgen Pharma (LSE:EVG)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Evgen Pharma (LSE:EVG)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024